Table 1.
Baseline characteristics of patients with early TNBC
| Characteristic | No. (%) (n=92) |
|---|---|
| Age (yr) | |
| Median (range) | 50.5 (26-73) |
| < 50 | 44 (47.8) |
| ≥ 50 | 48 (52.2) |
| Tumor stage | |
| cT1-2 | 81 (88.1) |
| cT3-4 | 11 (11.9) |
| Lymph node status | |
| Negative | 62 (70.5) |
| Positive | 26 (29.5) |
| Missing | 4 (4.3) |
| Tumor grade | |
| 1-2 | 23 (25.0) |
| 3 | 69 (75.0) |
| Histo subtype | |
| Ductal | 88 (95.7) |
| Others | 4 (4.3) |
| Treatment | |
| PM | 46 (50.0) |
| PMCb | 46 (50.0) |
| LPBC | 29 (31.5) |
| pCR | |
| ypT0/is_ypN0 | 48 (52.2) |
TNBC, triple-negative breast cancer; PM, paclitaxel plus nonpegylated liposomal doxorubicin; PMCb, PM combined with carboplatin; LPBC, lymphocyte-predominant breast cancer; pCR, pathological complete res-ponse.